Workflow
MBX Biosciences to Participate in June Investor Conferences

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform to advance its pipeline of candidates [3] Pipeline Development - The pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism in Phase 2 development [3] - MBX 1416 is in Phase 1 development for post-bariatric hypoglycemia [3] - An obesity portfolio includes MBX 4291, with an IND filing anticipated in Q2 2025, along with multiple discovery and pre-clinical obesity candidates [3] Upcoming Investor Conferences - Kent Hawryluk, President and CEO, will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 2:00 p.m. ET in New York, NY [1] - The company will also participate in the Goldman Sachs Global Healthcare Conference on June 9, 2025, with a podium presentation at 10:40 a.m. ET in Miami, FL [2] - Live webcasts of these events will be accessible on the MBX Biosciences website, with replays available for approximately 90 days [2]